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Background: The leading causes of morbidity and mortality for people in high-income countries living with HIV are
now non-AIDS malignancies, cardiovascular disease and other non-communicable diseases associated with ageing.
This protocol describes the trial of HealthMap, a model of care for people with HIV (PWHIV) that includes use of an
interactive shared health record and self-management support. The aims of the HealthMap trial are to evaluate
engagement of PWHIV and healthcare providers with the model, and its effectiveness for reducing coronary heart
disease risk, enhancing self-management, and improving mental health and quality of life of PWHIV.
Methods/Design: The study is a two-arm cluster randomised trial involving HIV clinical sites in several states in
Australia. Doctors will be randomised to the HealthMap model (immediate arm) or to proceed with usual care
(deferred arm). People with HIV whose doctors are randomised to the immediate arm receive 1) new opportunities
to discuss their health status and goals with their HIV doctor using a HealthMap shared health record; 2) access to
their own health record from home; 3) access to health coaching delivered by telephone and online; and 4) access
to a peer moderated online group chat programme. Data will be collected from participating PWHIV (n = 710) at
baseline, 6 months, and 12 months and from participating doctors (n = 60) at baseline and 12 months. The control
arm will be offered the HealthMap intervention at the end of the trial. The primary study outcomes, measured at
12 months, are 1) 10-year risk of non-fatal acute myocardial infarction or coronary heart disease death as estimated
by a Framingham Heart Study risk equation; and 2) Positive and Active Engagement in Life Scale from the Health
Education Impact Questionnaire (heiQ).
Discussion: The study will determine the viability and utility of a novel technology-supported model of care for
maintaining the health and wellbeing of people with HIV. If shown to be effective, the HealthMap model may
provide a generalisable, scalable and sustainable system for supporting the care needs of people with HIV,
addressing issues of equity of access.
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The changing health needs of people living with HIV
The population of people with HIV (PWHIV) is increas-
ing and ageing. Rates of new infection are increasing in
many high-income countries [1, 2], and the advent of ef-
fective combination antiretroviral therapy (cART) in
1996 resulted in a marked increase in life expectancy for
PWHIV [3–5]. In the coming decades these factors are
expected to result in a steady growth in HIV prevalence
and a marked increase in the number of people with
HIV living to older ages.
Despite increases in life expectancy, a substantial gap in
life span persists between treated individuals with HIV
and the general population [5–7]. In populations of
PWHIV with high treatment coverage the key drivers of
this gap in life expectancy and the majority of mortality
and morbidity is now due to non-AIDS-related non-
communicable diseases [8–10], particularly cardiovascular
disease and non-AIDS malignancies [11–17] PWHIV are
also at increased risk of other chronic medical conditions
such as liver disease [15, 17], renal disease [18, 19], de-
mentia [20], osteoporosis [21, 22] and depression [23, 24].
Cardiovascular risk is of particular concern. HIV infec-
tion appears to be independently associated with cardio-
vascular risk after adjustment for established risk factors
[25]. This may be due to residual immune activation as-
sociated with HIV infection despite the achievement of
virus suppression [26]. Some antiretroviral agents also
appear to contribute to cardiovascular risk, either inde-
pendently or in part mediated by an increased risk of
dyslipidaemia and insulin resistance [27, 28]. However,
the majority of excess cardiovascular risk in PWHIV is
due to a high prevalence of established modifiable risk
factors, particularly smoking and dyslipidaemia [29, 30].
Most studies of PWHIV in high-income countries indi-
cate smoking prevalence of 30-50 %, usually more than
double that in the general population [31]. Hypertension
and diabetes are also important risk factors for coronary
heart disease (CHD) both in HIV-infected and unin-
fected adults [32, 33].The increasing complexity of HIV care
The rising importance of prevention and management of
chronic non-communicable comorbidities and persist-
ently high levels of unmet psychosocial needs has re-
sulted in increasing complexity of HIV care [34]. In
response, health care services need to provide chronicdisease prevention and management and mental health
care alongside specific treatment for HIV itself [35, 36].
Data reporting the quality of care provided to patients
with HIV is sparse, but suggests an evidence-practice
gap in critical aspects of contemporary HIV care. In
Australia, an audit of 500 patients initiating cART at
four hospital and primary care sites suggested the con-
cordance between practice and guideline recommenda-
tions in these sites was generally high (>70 %) for HIV
treatment activities, but low (<50 %) for activities in rela-
tion to chronic co-morbidities [37, 38].
Persistent policy aspirations for HIV care to be pro-
vided from within a chronic care framework with an
emphasis on self-management [39] are yet to be broadly
realised. Only a few HIV-specific self-management sup-
port programmes have been developed [40–43] and link-
ages between these programmes and HIV treatment
services are rarely established, compounding fragmenta-
tion of care.Responding to the increasing complexity of HIV care: the
HealthMap model
The HealthMap model has been developed in response
to the gap between policy and the implementation of
critical aspects of care for PWHIV in practice. It links
the usual interactions of the existing care team to a set
of self-management support opportunities with the aim
of reducing the risk of coronary heart disease and im-
proving the psychosocial wellbeing of people with HIV.
The model includes 1) new opportunities for people
with HIV to discuss their health status and goals with
their doctor using the HealthMap shared health record;
2) access for people with HIV to their own health record
and contextual health information from home; 3) self-
management support delivered by telephone and online;
and 4) access to an online peer moderated group chat
programme.
It is intended that, by utilising within healthcare con-
sultations, an interactive software platform that provides
convenient access to patient health information, doctors
and their patients will more frequently and more easily
engage in conversations about the patient’s health status
and broader health priorities. The addition of self-
management support services integrated with patients’
usual primary health care is intended to supplement
health promotional activities in the health clinic and
Fig. 1 Flow chart of the study processes
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related goals.
Evaluation of the HealthMap model
This paper describes the protocol of a cluster rando-
mised controlled trial of the HealthMap model. These
are specific aims of the HealthMap trial:
Aim 1
Evaluate the effect of an interactive shared health record
and integrated self-management support on coronary
heart disease risk, disease self-management, mental
health and quality of life of PWHIV.
Aim 2
Evaluate patient and health care provider engagement
with, and acceptance of, an interactive shared health rec-
ord and integrated self-management support.
Aim 3
Evaluate the cost-effectiveness of an interactive shared
health record and integrated self-management support.
Hypothesis
The use of interactive, within-consultation decision sup-
ports and integrated self-management support will result
in improved cardiovascular risk and self-management
behaviours in people with HIV, and will be acceptable
and cost-effective.
Methods
Study design
The study is a two-arm cluster randomised controlled
trial of the HIV HealthMap model, with clustering ap-
plied at the level of the doctor. Doctors will be rando-
mised to the HealthMap model (immediate arm) or
proceed with usual care (deferred arm). Patients with
HIV will be allocated to the study arm to which their
usual HIV doctor has been randomised. Doctors and pa-
tients in the deferred arm will continue with usual care
until the end of the trial, after which they will be able to
access the HealthMap model. Data will be collected
from PWHIV participants (n = 710) at baseline,
6 months, and 12 months and from doctor participants
(n = 60) at baseline and at 12 months. A flow chart of
the study is presented in Fig. 1.
Study populations
Doctors are eligible to participate if 1) their clinic uses
electronic patient management systems capable of inte-
grating with HealthMap systems to enable capture of
pathology data; and 2) they provide care to a minimum
of five PWHIV. Patients are eligible to participate if 1)
they are aged 30 or over; 2) they receive primary HIVcare and general care from a participating doctor and
are likely to continue to do so for 12 months; 3) they do
not have diagnosed cardiovascular disease (i.e., coronary
health disease, stroke, transient ischaemic attack, or
peripheral arterial disease); 4) they have not previously
participated in an HIV-specific self-management or
coaching programme; and 5) they are willing and able to
provide written informed consent.
Study outcomes
All study outcomes are to be measured at the 12 month
follow-up visit. Secondary outcomes measured by an on-
line survey will also be measured at 6 months. The pri-
mary study outcomes are 1) 10-year risk of non-fatal
acute myocardial infarction or coronary heart disease
death as estimated by a Framingham Heart Study risk
equation [44]; and 2) their Positive and Active Engage-
ment in Life Scale score (one of eight scales of the
Health Education Impact Questionnaire heiQ) [45]. The
secondary study outcomes are as follows:
1) Cardiovascular risk relative to age as measured by
the Joint European Taskforce relative risk tables [46]
2) Cardiovascular risks estimated by an HIV-specific
risk score [28]
Dodson et al. BMC Infectious Diseases  (2016) 16:114 Page 4 of 113) Smoking status as measured by self-report and
verified by urinary cotinine in individuals who report
smoking at baseline and not smoking for at least 1
month prior to the 12 month visit [47, 48]
4) Fasting total cholesterol and total cholesterol to
HDL ratio (measured by serum assay)
5) Systolic blood pressure (measured using a
sphygmomanometer)
6) Body mass index (weight in kilograms divided by
height in metres squared) and waist circumference
(measured at the level of the umbilicus using a
flexible steel measuring tape)
7) Proportion of patients achieving Australian
cardiovascular risk factor management targets [49]
8) Health-related quality of life as measured by the
AQoL-4D instrument [50]
9) Mental health status as measured by the DASS-21
instrument [51]
10) Self-monitoring and insight as measured by the
heiQ [45]
11) Constructive attitudes and approaches as measured
by the heiQ [45]
12) Social integration and support as measured by the
heiQ [45]
13) HIV stigma coping strategies as measured by Herek
and colleagues HIV stigma scale [52]
14) Proportion of patients with HIV virus suppression
(below the lower limit of detection of the assay
used)
15) Proportion of patients achieving HIV quality of care
measures [53]
Study setting
The study will be conducted in HIV clinical sites across
Australia, including general practice clinics, public hos-
pitals and sexual health centres.
Recruitment procedures
Doctors will be identified using existing professional net-
works and national clinic data, and invited to participate
in the study. Eligible doctors, and research coordinators
will provide written consent, receive training in the con-
duct of the study, and participate in the development of
site-specific study procedures. Participating doctors and
research coordinators will approach potential patient
participants sequentially, describe the study, and ask
them to provide consent. The study will be promoted
through community and online channels.
Randomisation procedures
Cluster randomisation will be performed at the level of
treating doctor by a statistician, after stratification for
doctor type (general practitioner versus physician) and
number of enrolled patients (above and below median).Doctors will be randomly assigned 1:1 to either immedi-
ate (intervention arm) or deferred (control arm) access
to the intervention package. Random allocation will be
performed using the ‘ralloc’ program in the statistical
package Stata 13 [54].Intervention Training
Doctors randomised to the intervention arm will receive in-
dividual training regarding the use and integration of the
HealthMap platform within their clinical consultations.The HealthMap model
PWHIV in the immediate access arm of the study will
experience 1) new opportunities during their routine
clinic visits to discuss their health status and goals with
their doctor using the HealthMap shared health record;
2) access to their own health record and contextual
health information from home; 3) access to health
coaching delivered by telephone and online using the
SteppingUp health coaching programme [55] and 4) ac-
cess to an online peer moderated group chat programme
(Fig. 2).Component 1: Clinic visits using the HealthMap shared
health record
Participants will visit their HIV doctor as per their usual
schedule, typically every three to 6 months, to review
blood test results and obtain a prescription for cART
and other medications. At these visits, doctors and their
patients will use the HealthMap shared health record as
a tool for facilitating discussion about recent laboratory
test results and identifying health issues and areas where
the patient is interested in making changes. Specifically,
doctors will use the shared health record to:
1. Present recent laboratory results
2. Discuss the implications of these results
3. Agree upon and document health priorities with the
patient
4. Discuss strategies to address these health priorities
5. Refer patients to self-management support coaching
6. Review and track progress over time, making
adjustments to priorities and strategies as needed
Linkages between the ‘HealthMap health-planning
pages’, the ‘HealthMap PWHIV information and results
pages, and the ‘coach pages’ will allow common views of
key information between patients, coaches and pro-
viders. The HealthMap website is accessed via a secure
web browser. A screenshot of the doctor’s view of pa-
tient information is shown in Fig. 3.
Fig. 2 Intervention components – the HealthMap model
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record and information from home
All enrolled patient participants will be encouraged to
use the HealthMap shared health record outside of clinic
visits. The shared health record provides PWHIV with
access to their laboratory results captured from their
clinic health record, health priorities identified with their
doctor, and action plans to make health changes. In
addition, health information and links to additional re-
sources relevant to each individual’s health profile are
presented. A screenshot of the patient dashboard is
shown in Fig. 4. Specifically, patient participants will be
able to:
a. Review the laboratory results shown to them during
their clinic visit
b. Access information describing their health priorities,
goals and planned actions
c. Create or update action plans to address health goals
d. Document progress towards their health goals
e. Register interest in the health coaching programme
if they currently smoke or are at a high CHD riskFig. 3 A screenshot of the doctor’s view of patient informationf. Register interest in the online peer moderated group
chat
g. View details of upcoming coaching appointments (if
applicable)
h. Send messages to their health coach
i. Document areas of concern they wish to discuss
during their next clinic visit
j. Access patient education resources
Component 3. Telephone and online health coaching using
the SteppingUp health coaching programme
Patient participants identified as smokers or at
moderate-to-high risk of cardiovascular disease (>10 %
risk of cardiovascular disease over the following 5 years)
will be encouraged by their regular doctor and other
clinic staff to participate in phone and online self-
management support.
The self-management programme will be delivered by
telephone or via a secure online portal with email sup-
port from a coach. Patients enrolled into the coaching
programme will have an initial telephone assessment
that seeks to identify health knowledge and behaviours,
Fig. 4 A screenshot of the patient dashboard
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Flinders Program assessment tools form the basis of this
assessment process [56] The interview will also involve a
collaborative goal setting process. Where a patient opts
to engage with the coach supported online programme,
they will be assigned a series of tailored online learning
modules to work through at their own pace using the
SteppingUp online platform [55]. The assigned online
programme will be matched to the patient’s identified
treatment goal. A screenshot of the SteppingUp online
platform is shown in Fig. 5.
Patients will have access to the programme from be-
tween 4 and 12 weeks, depending on their needs and cir-
cumstances. Assessment and progress information will
be recorded by the coach in the HealthMap shared
health record and remain accessible to the coach and
treating doctor.Fig. 5 A screenshot of the SteppingUp online platformComponent 4. Online group chat
All enrolled patient participants will be invited to take
part in a peer moderated online chat group. Invitations
will come from clinic staff, as well as via prompts deliv-
ered in the HealthMap shared health record, and by
email and SMS. Patients will be able to register their
interest and will be assigned to a group suited their spe-
cified gender or sexual identity preference. An experi-
enced peer moderator will manage enrolments, assign
patients to appropriate groups, and make contact with
patients with commencement details. Each chat group
will involve a two-hour moderated online chat session,
once per week for 6 weeks. Up to 10 participants will be
enrolled in each group. Sessions will be based on the
Positive Outlook Program [57] and focus on pre-
assigned topics including issues of disclosure of HIV sta-
tus and negotiating intimate relationships.
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Baseline visit
Following randomisation, recruited patient participants
will be asked to attend a baseline study visit. Participants
will be asked to complete an online survey prior to the
study visit or during the study visit. The survey includes
measures of 1) health-related quality of life, 2) chronic
disease self-management, 3) mental health, 4) health
behaviours (smoking and physical activity), and 5) HIV
stigma. During the study visit, clinical and demo-
graphic data will be collected by site staff and blood
pressure, weight, height and waist circumference will
be measured.
Six month follow-up
Participating PWHIV will be emailed or sent a text
message by HealthMap research staff asking them to
complete the online survey. The window for this data
collection will be 6 to 8 months.
Upon completion of programme components
PWHIV who participate in the telephone and online
self-management support, or the online moderated
group chat components will be asked to complete online
surveys at completion of these activities. These surveys
will enquire about patient’s satisfaction with these com-
ponents, and their perception of the degree of benefit
gained from their engagement with these intervention
components.
In addition to these surveys, a minimum of ten partici-
pants of the self-management support component, and a
minimum of ten of the online group chat component
who have previously consented to be contacted for a
telephone interview will be selected to take part in a
semi-structured interview. Participants exposed to both
components will not be approached for interview. The
interviews will focus on four key areas: 1) current
healthcare management practices; 2) communication
and joint decision making with doctors; 3) engagement
and adherence to self-defined goals and other recom-
mended healthcare activities; and 4) sources of informa-
tion and support. Participants’ experiences with the
HealthMap platform, self-management support and on-
line chat groups will also be explored.
Twelve month follow-up
Participating PWHIV will be asked to attend a study
visit 10 to 14 months following their baseline visit. Dur-
ing this visit, clinical data collected at baseline will be
repeated. Additionally, a urine sample will be collected
from participants who reported smoking at baseline
and smoking abstinence for at least 1 month prior to
the 12 month visit. Patients will be asked to completethe online survey prior to the study visit or during the
study visit.
A minimum of ten participants will also be selected to
take part in a semi-structured interview. Participants taking
part in the optional telephone and online self-management
support component or the online moderated group chat
component will not be approached. These interviews will
follow the same structure as those conducted with partici-
pants of the additional programme components.
Data collection from participating service providers
Baseline
Participating doctors will complete a survey at baseline
that includes details of their HIV experience and work-
load and current chronic disease management practice.
Twelve months from baseline
All intervention arm doctors, coaches and peer chat
moderators will be asked to complete a short online sur-
vey about their experiences of the HealthMap model.
Coaches, peer chat moderators and a minimum of ten
intervention doctors will also be invited to participate in
semi-structured interviews. These interviews will focus
on their general experience of the HealthMap model,
perceptions of effectiveness, clinical burden, and imple-
mentation issues associated with delivery of each Health-
Map intervention component.
Data collection from the online platforms
The following data will be extracted from the online
platforms (i.e., the main HealthMap electronic shared
health record, the moderated group chat, and the self-
management support): number, frequency and distribu-
tion of participant and doctor logins, individual
webpage views, participation and posts in the online
groups, and interactions between health coaches and
patient participants.
Sample size calculation
For the co-primary outcome of CHD risk, we used the pri-
mary dataset of STEAL (n = 280; J. Amin, personal com-
munication), a multi-site Australian HIV clinical trial [58]
to estimate a geometric mean (due to skewed distribution)
Framingham 10 year coronary heart disease risk [44] of
6.3 % units with standard deviation of 0.70 (loge %units)
and an intra-class correlation coefficient of 0.058. We then
evaluated the Framingham 10 year coronary heart disease
after we enrolled 563 participants. The geometric mean
(due to skewed distribution) Framingham 10 year coron-
ary heart disease risk was 6.9 % units with standard devi-
ation of 0.72 (loge %units) and an intra-class correlation
coefficient of 0.09 (to account for the differences in CHD
risk between the doctors). We estimated a minimum clin-
ically important relative reduction of 24 % in Framingham
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ment [59] and cardiovascular risk management studies
[60]. We conservatively estimated loss to follow up to the
12 month primary outcome as 15 %, five times the 96 week
loss to follow up in the STEAL study [58]. Using cluster-
sampsi in Stata (Version 12, College Station, TX, USA)
and using a coefficient of variation of 1 (to account for the
variation in the number of patients enrolled per doctor),
we calculated that to provide 80 % power at a 5 % signifi-
cance level (two-sided) we will require 60 doctors and a
total sample size of 710 patients (355 per arm and an aver-
age 12 patients per doctor).
For the co-primary outcome of the Positive and Active
Engagement in Life (PAEL), we used the primary dataset
from an archived dataset held within Deakin University’s
heiQ database. The most comparable intervention was
selected from among hundreds of known interventions
to match the likely impact of HealthMap. The dataset
included n = 212 individuals who had an absolute mean
gain in PAEL of 0.35 units with a standard deviation of
0.46 in the intervention group. Using clustersampsi in
Stata (Version 12, College Station, TX, USA), a coeffi-
cient of variation of 1 for size of cluster and an intra-
class correlation coefficient of 0.09, we calculated that
to provide 80 % power at a 5 % significance level (two-
sided) we will require 60 doctors and a total sample size
of 142 patients (71 per arm and an average 2 patients
per doctor). This sample size allows for a 15 % loss to
follow up rate.Data and safety monitoring board
A Data and Safety Monitoring Board (DSMB) and Proto-
col Steering Committee (PSC) will be established. The
DSMB will consist of a statistician, an experienced HIV
clinician and a cardiologist, without previous involve-
ment in the trial. The DSMB will oversee the baseline
coronary heart risk in study participants and provide ad-
vice as to whether the projected power of the study is
likely to be achieved. Interim summary coronary heart
risk data collected at the time of enrolment will be sub-
mitted to the DSMB after 25, 50 and 75 % of partici-
pants have been enrolled.Ongoing reporting
Doctors, other study site staff, coaches and modera-
tors will record issues arising during the study in an
issues log and report significant issues to the Health-
Map study team within 24 h. The HealthMap study
team will report all significant incidents to Human
Research Ethics Committees within 72 h of the inci-
dent. All incidents will also be reported to the Proto-
col Steering Committee.Data analysis
All statistical analyses will be conducted using Stata 13
[54] according to the pre-specified plan below. All of the
primary and secondary outcomes are measured at the
individual level and therefore we will use Generalised
Estimating Equations (GEEs) to allow for the clustering
due to randomisation at the doctor level.
Examination of primary outcomes
The distribution of Framingham risk scores and PAEL
are typically skewed, so scores will be loge transformed
where necessary. An estimate and 95 % confidence inter-
val of the relative difference in geometric mean (at
12 months) between the intervention and control groups
will be derived using linear regression, with adjustment
for baseline scores and fitting using GEEs to allow for
clustering by doctor.
Examination of secondary outcomes
For the continuous secondary outcomes measured at the
six and/or 12 month visit: coronary heart risk (relative
to age and as estimated by HIV-specific risk score); fast-
ing total cholesterol and total cholesterol: HDL ratio;
systolic blood pressure; body mass index and waist cir-
cumference; and quality of life and mental health status
scores; an estimate of the absolute mean difference (or
relative difference in geometric means for outcomes with
a lognormal distribution) and 95 % confidence interval
between the intervention and control groups will be de-
rived by linear regression using GEE (to account for
clustering by doctor) with adjustment for, where applic-
able, baseline measures of the secondary outcome.
For the binary secondary outcomes measured at the
12 month visit: smoking status (smoker versus non-
smoker); achievement of Australian cardiovascular risk
factor management targets (yes versus no); HIV virus
suppression (yes versus no); and achievement of HIV
quality of care measures (yes versus no); an estimate of
the Odds Ratio (OR) and 95 % confidence interval for
the intervention compared to the usual care will be de-
rived by logistic regression modelling using GEEs, to allow
for clustering by doctor. To identify latent HR-QoL and
self-management profiles at baseline, Latent Profile Ana-
lysis will be conducted using MPlus software package
(ref). Associations between latent profiles at baseline and
both demographic characteristics and change on binary
secondary outcomes will be identified. This approach will
allow intervention responsiveness to be explored within
the context of baseline self-management practices and
functioning.
Economic evaluation
The health economic analysis will estimate the cost-
effectiveness of the intervention relative to standard
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ease risk, but also in terms of improving life expectancy
and quality of life. The economic evaluation will be con-
ducted alongside the clinical trial and a Markov model
will be employed to extrapolate beyond the trial period
to estimate lifetime cost effectiveness. Resource use and
costs associated with providing standard care and the
management plans will be collected and compared. Re-
source use will be valued using standard reference pri-
cing and unit costs, primarily by using the Medicare
Benefits Scheme and the Pharmaceutical Benefits
Scheme, the mechanisms by which the Australian gov-
ernment funds specific health care. Total costs will be
estimated at an individual level, and average costs will
be compared between the two study arms.
The relationship between costs and outcomes will be
considered and incremental cost effectiveness ratios
(ICERs) estimated, for the trial period and over a lifetime.
The within trial analysis will use absolute change in cor-
onary heart disease risk and a generic quality of life meas-
ure, the AQoL-4D [50] to estimate quality adjusted life
years (QALYs). Cost per reduction in coronary heart risk
and cost per QALY gained will be estimated. Sensitivity
analyses will be undertaken, using non-parametric boot-
strapping, to understand the uncertainty surrounding the
ICER estimates.
To understand the long-term cost effectiveness of each
intervention it will be necessary to extrapolate and model
future events. Estimated risk reductions for each patient
in the intervention and control groups will be extrapolated
to life years saved using a Markov type model which con-
verts risk reductions into events avoided (using published
evidence) and then into life years saved over the patient’s
lifetime. The trial AQoL and QALYs estimates will supple-
ment estimates from the literature of the utility reduction
associated with various coronary heart events, and the
Markov model will estimate the QALYs gained over a life-
time. These lifetime estimates of effect will be combined
with costs to generate a measure of the cost per life year
saved and cost per QALY gained associated with the inter-
vention, thereby determining the long-term cost effective-
ness of interactive self-care plans and self-management
support for PWHIV.
Management of missing data
The distribution of the baseline characteristics and out-
come measures recorded at baseline will be presented
for those with and without data available at the 12 month
follow-up, and compared using multivariable logistic re-
gression where the outcome variable is data available at
12 month follow-up visit (yes versus no). If the propor-
tion of missing data at the 12 month visit is <10 %, then
a complete-case analysis will be performed (i.e., those
participants with missing data are excluded from thestatistical analysis). Otherwise, two statistical approaches
will be considered for handling the missing data: a
complete-case analysis as the primary analysis and the ap-
plication of multiple imputation as a sensitivity analysis
[61]. For the imputation stage of multiple imputation, the
imputation model will be developed based on the main
analysis model, the findings of the multivariable logistic
regression above of the baseline covariates for consider-
ation of auxiliary variables, and the data available from the
6 month online survey. Reporting will adhere to the guide-
lines suggested by Sterne JAC et al. [62].
Management of qualitative data
Qualitative interview data will be transcribed verbatim
and identifying details anonymised. Data will be entered
into NVivo 10 (QSR International Pty Ltd, 2012) and
coded for a structured thematic analysis. Demographic
and health status data from patients will be used to iden-
tify patterns of experience.
Ethical approval
This study has received ethical approval from Alfred Health
Human Ethics Committee (520/13), the Royal Australian
College of General Practitioners (NREEC 13–015),
Monash University Human Research Ethics Committee
(CF14/925–2014000367) and the Australian Department
of Health Ethics Committee (SF4060527).
Trial registration
The trial is registered at clinicaltrials.gov (NCT02178930)
and anzctr.org.au (U1111-1150-6489).
Discussion
The HealthMap model of care aims to encourage people
with HIV and their doctors to engage more actively in
addressing the risk factors that contribute to the high
coronary heart risk observed in PWHIV. This cluster
randomised control study seeks to determine the effect-
iveness of the HealthMap model of care in reducing cor-
onary health disease risk, improving self-management,
mental health and quality of life of PWHIV. It also seeks
to evaluate provider and patient engagement with the
model’s components, and the acceptability and cost-
effectiveness of this approach to care.
The study will contribute to our understanding of the
feasibility and effectiveness of novel chronic care ap-
proaches to the management of HIV and the benefit and
impact of introducing interactive software components
into clinical consultations for enhanced chronic disease
management. If shown to be effective and cost-effective,
the HealthMap model of care may provide a generalis-
able, scalable and sustainable system for improving the
long term health of people with HIV, assuring the quality
and safety of HIV care, supporting healthcare worker
Dodson et al. BMC Infectious Diseases  (2016) 16:114 Page 10 of 11engagement in HIV care provision, and improving equity
of access to high quality HIV care programmes.
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